Prevention of Tetanus

In this trial, we are evaluating the safety and tolerability of an experimental new medicine. The medicine is an injection being developed to prevent tetanus. This injection is a human monoclonal antibody against tetanus toxin. Monoclonal antibodies are a type of protein or antibody that is produced by a single clone of cells, these antibodies or proteins will only bind to one substance or foreign body. The study drug or a placebo will be administered as an intramuscular (into the muscle) injection.

Recruitment for this study is now complete.  Thank you to everyone who has participated.

– A healthy male or healthy female who is not pregnant or who cannot bear children
– Aged 18-55 (inclusive)
– BMI 18-32 (inclusive) kg/m2
– Able to comply with contraception requirements
– a non-smoker, or smoker of no more than 5 cigarettes or equivalent per day and are able to abstain from smoking from 48 hours prior of study drug administration and for the duration of the whole study.
– Have no history of alcohol or drug abuse